Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis


  • Tarja Mälkönen Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
  • Pauliina Nuutinen
  • Taru Hallinen
  • Erkki Soini
  • Riikka Nissinen
  • Christina Wennerstöm
  • Tapio Rantanen
  • Johanna H. Hagman
  • Rauno Harvima
  • Johanna Höök-Nikanne
  • Tiina Ilves
  • Päivi Lintu
  • Ken Malanin
  • Iina Soramäki
  • Kaisa Tasanen
  • Arja Teho
  • Katja Vähävihu
  • Sari Itälinna
  • Pekka Leinonen
  • Piia Sarajärvi
  • Laura Huilaja
  • Rafael Pasternack



psoriasis, guselkumab, treatment outcome, real-world, persistence


Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.


Download data is not yet available.


Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-729. DOI:

Griffiths CE, Papp KA, Song M, Miller M, You Y, Shen YK, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat 2020; 13: 1-9. DOI: DOI:

Psoriasis (skin and joints). Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Dermatological Society. Helsinki: The Finnish Medical Society Duodecim, 2020 [cited 2021 Feb 10]. Available in Finnish from:

Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al.; BADBIR study group and the PSORT consortium. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166. DOI:

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, et al. Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol 2019; 20: 155-164. DOI:

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405-417. DOI:

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418-431. DOI:

Maliyar K, O'Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg 2020; 24: 588-595. DOI:

Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med 2020; 9: 2170. DOI:

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther 2021; 34: e14798. DOI:

Schwensen JFB, Nielsen VW, Nissen CV, Sand C, Gniadecki R, Thomsen SF. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol 2021; 35: e341-e343. DOI:

Gerdes S, Brau B, Hoffman M, Korge B, Mortazawi D, Wiemers F, et al. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol 2021; 48: 1854-1862. DOI:

Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol 2021; 22: 567-579. DOI:

Iznardo H, Vilarrasa E, Lopez-Ferrer A, Puig L. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol 2021; 185: 640-682. DOI:

Additional Files



How to Cite

Mälkönen, T., Nuutinen, P., Hallinen, T., Soini, E., Nissinen, R., Wennerstöm, C., Rantanen, T., Hagman, J. H., Harvima, R., Höök-Nikanne, J., Ilves, T., Lintu, P., Malanin, K., Soramäki, I., Tasanen, K., Teho, A., Vähävihu, K., Itälinna, S., Leinonen, P., Sarajärvi, P., Huilaja, L., & Pasternack, R. (2022). Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Dermato-Venereologica, 102, adv00631.





Most read articles by the same author(s)

1 2 3 4 5 > >>